Baltimore-based QuartzBio has received a growth investment from private equity firm Eir Partners in a deal that gives the healthcare-focused investment firm a controlling interest in the company as demand continues rising for artificial intelligence tools supporting clinical development and drug research.
Financial terms of the transaction were not disclosed.
QuartzBio develops AI-driven biomarker intelligence and analytics software designed to help biotechnology and pharmaceutical companies manage and interpret large volumes of clinical trial data. The company’s platform focuses on improving data integration, analysis and operational efficiency across clinical development programs.
The investment comes as pharmaceutical companies increasingly seek AI-powered solutions capable of streamlining clinical trials, reducing development costs and accelerating drug discovery timelines amid growing data complexity across the healthcare sector.
QuartzBio CEO Scott Marshall said the new capital will support expansion of the company’s software platform and continued development of automation tools designed to reduce manual oversight and improve data reliability within clinical research operations.
“Modern clinical development generates unprecedented volumes of data, yet trial risk persists because that data is fragmented, delayed, or unreliable,” Marshall said in the announcement. “This investment allows us to double down on delivering a scalable software platform that removes manual oversight, protects scientific integrity, and materially reduces trial cost and duration.”
QuartzBio’s platform is designed to support biomarker-driven research and precision medicine initiatives by helping life sciences companies organize and analyze complex datasets generated during clinical trials and drug development programs.
The transaction reflects continued investor interest in healthcare technology companies leveraging artificial intelligence, machine learning and advanced analytics to improve pharmaceutical research, diagnostics and clinical operations.
Eir Partners, which focuses on healthcare and life sciences investments, has been active in backing companies operating across pharmaceutical services, healthcare technology and medical innovation sectors.
The investment also adds to Baltimore’s growing presence within the biotechnology and healthcare technology ecosystem, where companies increasingly are developing AI-enabled platforms tied to medical research, diagnostics and life sciences infrastructure.
